{
  "schemaVersion": 1,
  "id": "research-370",
  "slug": "370-what-the-current-u-s-label-means-by-excess-abdominal-fat",
  "title": "What the current U.S. label means by excess abdominal fat",
  "catalogLabel": "Tesamorelin",
  "productCollection": "https://heritagebiolabs.com/research-library/products/tesamorelin",
  "productHandles": [
    "tesamorelin-676",
    "tesamorelin-538",
    "tesamorelin-675"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/tesamorelin-676",
    "https://heritagebiolabs.com/product/tesamorelin-538",
    "https://heritagebiolabs.com/product/tesamorelin-675"
  ],
  "readingFocus": "Methods & identity",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 352,
  "sourceYears": [
    2010,
    2026
  ],
  "paragraphs": [
    "Peptides are short amino-acid chains joined by peptide bonds. Some imitate natural signals that tell the pituitary to release a hormone. Tesamorelin is a synthetic analogue of human growth hormone–releasing factor. It contains the 44-amino-acid sequence of that hormone and an added chemical group at the beginning. What does the approved indication mean when it describes a reduction in excess abdominal fat? [1]",
    "The July 2026 U.S. prescribing information for Egrifta WR specifies adults with HIV who have lipodystrophy and excess abdominal fat. Lipodystrophy describes abnormal distribution of fat. The trials behind the labeling used imaging to assess visceral fat, which is stored around organs in the abdomen. The amount of fat under the skin, the amount of fat in a different part of the body and a person's total weight are separate measurements. The label describes the drug as having a weight-neutral effect and gives a specific approved indication rather than an indication for general weight loss. [1, 2]",
    "The clinical trials also measured hormone and safety outcomes. By stimulating growth hormone release, tesamorelin can raise circulating insulin-like growth factor 1 (IGF-1). The label describes uncertainty about prolonged IGF-1 elevations and identifies risks including glucose intolerance, fluid retention and hypersensitivity. Some of the outcomes measured in the trials, such as blood glucose and reports of discomfort, help characterize risk separately from changes in abdominal fat. [1]",
    "A reduced amount of visceral fat can be demonstrated with imaging during a trial. Whether it changes cardiovascular events over a much longer period requires a separate comparison. The current label explicitly states that long-term cardiovascular safety has not been established. It also treats Egrifta WR and Egrifta SV as distinct formulations with separate prescribing information. Shared active ingredients do not make all details of formulation and evidence interchangeable. [1]",
    "The current U.S. label describes a specified product, purpose and patient group. Older randomized evidence supports the visceral-fat outcome in the studied population. It does not show that a different product bearing the same ingredient name has the same characteristics or that the same effect applies to every reason for gaining abdominal fat. [1, 2]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "Theratechnologies. EGRIFTA WR- tesamorelin kit. U.S. prescribing information on DailyMed (updated 2026-07-29).",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75"
    },
    {
      "number": 2,
      "citation": "Falutz J et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes (publication 2010-03).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/20101189/"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/370-what-the-current-u-s-label-means-by-excess-abdominal-fat",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/370-what-the-current-u-s-label-means-by-excess-abdominal-fat.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/370-what-the-current-u-s-label-means-by-excess-abdominal-fat.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 074 - TB-500 and Tesamorelin.docx",
    "sourceArticleNumber": 370,
    "contentSha256": "27e26f717276bc30a94b58c58c707eab0f3ef837419ea821786212f31769426b",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
